Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Johnson and Johnson
AstraZeneca
Harvard Business School
Moodys

Last Updated: December 7, 2022

CLINICAL TRIALS PROFILE FOR CABOMETYX


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Cabometyx

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01708954 ↗ Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Active, not recruiting National Cancer Institute (NCI) Phase 2 2013-02-13 This randomized phase II trial studies how well giving erlotinib hydrochloride and cabozantinib-s-malate alone or in combination works as second or third line therapy in treating patient with stage IV non-small cell lung cancer. Erlotinib hydrochloride and cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving erlotinib hydrochloride together with cabozantinib-s-malate is more effective than erlotinib hydrochloride or cabozantinib-s-malate alone in treating non-small cell lung cancer.
NCT01709435 ↗ Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Completed National Cancer Institute (NCI) Phase 1 2012-11-14 This phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01716715 ↗ Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed National Cancer Institute (NCI) Phase 2 2012-11-06 This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether cabozantinib-s-malate or paclitaxel is more effective at treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer.
NCT01811212 ↗ Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed Exelixis Phase 2 2013-05-08 This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor.
NCT01811212 ↗ Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed National Cancer Institute (NCI) Phase 2 2013-05-08 This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor.
NCT01822522 ↗ Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus Active, not recruiting National Cancer Institute (NCI) Phase 1 2013-06-21 This phase I trial studies the side effects and best dose of cabozantinib s-malate in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment and human immunodeficiency virus. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cabometyx

Condition Name

Condition Name for Cabometyx
Intervention Trials
Renal Cell Carcinoma 7
Metastatic Renal Cell Carcinoma 6
Hepatocellular Carcinoma 4
Recurrent Malignant Solid Neoplasm 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cabometyx
Intervention Trials
Carcinoma 45
Carcinoma, Renal Cell 23
Neoplasms 11
Neuroendocrine Tumors 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cabometyx

Trials by Country

Trials by Country for Cabometyx
Location Trials
United States 736
Australia 27
Spain 27
Italy 25
Germany 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cabometyx
Location Trials
California 30
Pennsylvania 26
New York 26
Missouri 24
Illinois 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cabometyx

Clinical Trial Phase

Clinical Trial Phase for Cabometyx
Clinical Trial Phase Trials
Phase 3 6
Phase 2 57
Phase 1/Phase 2 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cabometyx
Clinical Trial Phase Trials
Recruiting 39
Active, not recruiting 15
Completed 10
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cabometyx

Sponsor Name

Sponsor Name for Cabometyx
Sponsor Trials
National Cancer Institute (NCI) 32
Exelixis 26
Ipsen 7
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cabometyx
Sponsor Trials
Other 65
Industry 55
NIH 32
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Johnson and Johnson
AstraZeneca
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.